**Supplementary Table 2. Baseline patient demographics and clinical characteristics (supporting analysis set, N=569)**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **sP-controlled patients (n=426)** | **sP-uncontrolled patients (n=143)** |
| Mean (SD) age, yearsa | 58.3 (13.0)\* | 50.6 (13.4) |
| Male, n (%)b | 248 (58.2) | 79 (55.2) |
| Race, n (%)b  White Black/African American Asian Native Hawaiian or other pacific islander Other | 321 (75.4)  92 (21.6) 8 (1.9) 2 (0.5) 3 (0.7) | 111 (77.6) 29 (20.3) 2 (1.4) 0 (0.0) 1 (0.7) |
| Ethnicity, n (%)b  Non-Hispanic Hispanic or Latino | 370 (86.9)  56 (13.1) | 126 (88.1) 17 (11.9) |
| Region, n (%)b  US EU ROW | 219 (51.4%) 86 (20.2) 121 (28.4) | 70 (49.0) 19 (13.3) 54 (37.8) |
| Mean (SD) weight, kga | 80.6 (18.7)\* | 86.6 (20.5) |
| Mean body mass index, kg/m2,a | 28.3 (6.3)\* | 30.3 (6.9) |
| Reasons for ESRD, n (%)b  Hypertension Glomerulonephritis Diabetic nephropathy Pyelonephritis Polycystic kidney disease Interstitial nephritis Hydronephrosis Congenital Other | 117 (27.5) 81 (19.0) 119 (27.9) 15 (3.5) 32 (7.5) 12 (2.8) 6 (1.4) 5 (1.2) 39 (9.2) | 31 (21.7) 35 (24.5) 39 (27.3) 7 (4.9) 14 (9.8) 6 (4.2) 1 (0.7) 1 (0.7) 9 (6.3) |
| Months since ESRD diagnosis, median (range)a,c | 48.4 (0.4–396.8) | 40.0 (3.2–301.2) |
| Months since first dialysis, mean (range)a,d | 37.5 (2.5–396.8) | 37.1 (0.7–231.5) |
| HD, n (%)b | 387 (90.8) | 134 (93.7) |
| PD, n (%)b | 39 (9.2) | 9 (6.3) |
| HD Kt/V value, mean (SD)a | 1.6 (0.3)\* | 1.5 (0.2) |
| PD Kt/V value, mean (SD)a | 2.3 (0.7) | 2.1 (0.4) |
| Mean (SD) HD duration per session, hours | 3.9 (0.5) | 3.9 (0.5) |
| Average daily tablets taken, mean (SD)a | 5.1 (3.1) | 6.0 (4.3) |
| Vitamin D, mean (SD)a  25-hydroxyvitamin D, nmol/L 1,25-hydroxyvitamin D, pmol/L | 58.1 (32.3)  36.6 (33.6)\* | 60.2 (32.4) 32.9 (25.7) |
| Bone resorption markers, mean (SD)a  TRAP5b, U/L CTx, ng/mL | 5.3 (2.5)\* 3.0 (2.2) | 4.4 (2.4) 2.9 (2.2) |
| Bone formation markers, mean (SD)a  Bone-specific alkaline phosphatase, ng/mL Osteocalcin, ng/mL | 16.1 (12.9) 14.5 (15.8) | 14.4 (10.9) 15.7 (18.4) |
| Mean (SD) serum albumin, g/L | 40.8 (3.1) | 40.9 (3.4) |
| Mean (SD) serum total protein, g/L | 67.3 (5.3)\* | 68.6 (5.5) |

\**p*<0.05. aWilcoxon rank sum test. bCochran–Mantel–Haenszel testing. cTime since ESRD is the difference between the date of ESRD diagnosis and the date of the screening visit. dTime since first dialysis is the difference between the date of the first dialysis and the date of screening visit for initial 24-week Phase 3 study.

In the supporting analysis set, sP-controlled were defined as patients for whom two-thirds of serum phosphorus readings taken between Week 12 and Week 52 were ≤5.5 mg/dL; sP-uncontrolled were defined as patients for whom two-thirds of serum phosphorus readings taken in the same time period were >6.0 mg/dL. CTx, carboxyterminal crosslinking telopeptide; ESRD, end-stage renal disease; HD, hemodialysis; PD, peritoneal dialysis; ROW, rest of the world; SD, standard deviation; sP, serum phosphorus; TRAP5b, tartrate-resistant acid phosphatase 5b.